Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Serrapeptase is a proteolytic enzyme originally isolated from the bacterium Serratia marcescens found in the intestine of silkworms. It has been investigated for its anti-inflammatory, mucolytic, and fibrinolytic properties. In the context of the bronchial system, serrapeptase is primarily explored for its potential to help reduce the viscosity of mucus, thereby supporting the clearance of secretions in conditions such as chronic bronchitis, sinusitis, or other respiratory tract diseases.

There are a handful of small clinical studies, mostly from Europe and Asia, suggesting that serrapeptase may reduce sputum viscosity and ease expectoration in patients with chronic airway diseases. For example, a 2004 study in the journal Respirology found that serrapeptase improved sputum characteristics and reduced cough frequency in patients with chronic airway disease compared to placebo. However, these studies are generally small, of short duration, and sometimes lack rigorous double-blind methodology. Systematic reviews acknowledge the potential of serrapeptase as a mucolytic but consistently note the need for larger, high-quality trials.

Overall, there is some scientific rationale and limited clinical evidence supporting the use of serrapeptase for bronchial health, particularly as a mucolytic agent. However, the quality and quantity of the evidence are not strong, and serrapeptase is not universally recommended by medical guidelines for this purpose.

More about Serrapeptase
More about Bronchials

Other ingredients that support Bronchials

Other body systems supported by Serrapeptase

Products containing Serrapeptase